Filing Flows › AIM ImmunoTech (AIM) › Q1 2026
AIM ImmunoTech (AIM) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 15, 2026
AIM ImmunoTech (AIM) reported revenue of $22K for the first quarter 2026 (Q1 2026), +38% from a year earlier and +5% from the quarter before.
AIM ImmunoTech, Q1 2026: revenue $22K (+38% year over year), net loss $3.0M, operating cash flow −$2.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $22K | +5% | +38% |
| Operating profit | −$2.2M | — | — |
| Net earnings | −$3.0M | — | — |
| Operating cash flow | −$2.7M | — | — |
What changed
Revenue was $22K in Q1 2026, up 38% year over year and up 5% from the previous quarter.
Operating costs exceeded revenue by $2.2M, an operating margin of -10118.2%. Total costs fell 38% while revenue rose 38%. The quarter ended with a net loss of $3.0M, narrower than the previous quarter's $4.2M loss.
Operating cash flow was −$2.7M. Non-cash charges added back $43K of depreciation and amortization. Working capital and other items added $261K.
Questions
What was AIM ImmunoTech's revenue in the first quarter 2026?
AIM ImmunoTech (AIM) reported revenue of $22K for the first quarter 2026 (Q1 2026), +38% from a year earlier and +5% from the quarter before.
Source: AIM ImmunoTech 10-Q on SEC EDGAR.